Regenxbio Inc (NASDAQ:RGNX) price on current trading day, fall -4.59% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.74.
A look at the stock’s price movement, the close in the last trading session was $9.16, moving within a range at $8.44 and $9.27. The beta value (5-Year monthly) was 1.232. Turning to its 52-week performance, $28.80 and $8.53 were the 52-week high and 52-week low respectively. Overall, RGNX moved -2.02% over the past month.
Regenxbio Inc’s market cap currently stands at around $433.02 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 23.45M for the company’s revenue for the quarter, with a low and high estimate of 15M and 31M respectively. The average forecast suggests up to a 5.56% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 86.88M, representing a -3.73% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RGNX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend RGNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RGNX’s current price about -12.69% and -11.22% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.37, while 7-day volatility ratio is 6.49% and 9.03% in the 30-day chart. Further, Regenxbio Inc (RGNX) has a beta value of 1.25, and an average true range (ATR) of 0.78. Analysts have given the company’s stock an average 52-week price target of $38, forecast between a low of $18 and high of $40. Looking at the price targets, the low is -105.95% off current price level while to achieve the yearly target high, price needs to move -357.67%. Nonetheless, investors will most likely welcome a -334.78% jump to $38 which is the analysts’ median price.
If we refocus on Regenxbio Inc (NASDAQ:RGNX), historical trading data shows that trading volumes averaged 0.69 over the past 10 days and 667.81K over the past 3 months. The company’s latest data on shares outstanding shows there are 49.53 million shares.
The 9.50% of Regenxbio Inc’s shares are in the hands of company insiders while institutional holders own 90.28% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.62 million on 2024-11-15, giving us a short ratio of 7.31. The data shows that as of 2024-11-15 short interest in Regenxbio Inc (RGNX) stood at 1218.00005 of shares outstanding, with shares short falling to 4.99 million registered in 2024-10-15. Current price change has pushed the stock -51.31% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RGNX stock continues to rise going into the next quarter.
